Your browser doesn't support javascript.
loading
Two-dimension Tailor-made Therapy: A New Salvage Therapy After Multiple Eradication Failures for Helicobacter pylori Infection.
Nakajima, Shigemi; Inoue, Hisayuki; Satake, Hiroshi; Chatani, Rena; Ohara, Mariko; Tsubakimoto, Yuki; Fujii, Makoto; Hasegawa, Hiroshi; Takahashi, Keiko; Hayafuji, Kiyoyuki; Fujiyama, Yoshihide.
Afiliación
  • Nakajima S; Consortium for Community Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Inoue H; Department of General Medicine, Japan Community Healthcare Organization (JCHO) Shiga Hospital, Otsu, Shiga, Japan.
  • Satake H; Department of Gastroenterology, Japan Community Healthcare Organization (JCHO) Shiga Hospital, Otsu, Shiga, Japan.
  • Chatani R; Inoue Clinic, Moriyama, Shiga, Japan.
  • Ohara M; Satake Clinic, Kusatsu, Shiga, Japan.
  • Tsubakimoto Y; Consortium for Community Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Fujii M; Department of Gastroenterology, Japan Community Healthcare Organization (JCHO) Shiga Hospital, Otsu, Shiga, Japan.
  • Hasegawa H; Consortium for Community Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Takahashi K; Department of Gastroenterology, Japan Community Healthcare Organization (JCHO) Shiga Hospital, Otsu, Shiga, Japan.
  • Hayafuji K; Consortium for Community Medicine, Shiga University of Medical Science, Otsu, Shiga, Japan.
  • Fujiyama Y; Department of Gastroenterology, Japan Community Healthcare Organization (JCHO) Shiga Hospital, Otsu, Shiga, Japan.
Gastro Hep Adv ; 1(2): 210-222, 2022.
Article en En | MEDLINE | ID: mdl-39131120
ABSTRACT
Background and

Aims:

Vonoprazan-based eradication therapies have a higher eradication rate than usual proton pump inhibitor (PPI)-based therapies in treating Helicobacter pylori infection. Should we use vonoprazan to treat patients who failed multiple eradication therapies? Because the drug is not available in most countries, we propose 2-dimension tailor-made therapy (2dTMT) without using vonoprazan.

Methods:

Patients who failed twice or more PPI-based triple therapies were recruited. Patients underwent CYP2C19 genotype and antibiotic susceptibility tests (ASTs). PPI doses per day were decided as per the CYP2C19 genotype twice for poor and 4 times for extensive metabolizers (dimension 1). Two antibiotics were selected as per the results of the AST in each patient (dimension 2). Regimens of 2dTMT included 2 susceptible antibiotics and a PPI. For those who could not have enough information with the AST, tailor-made PPI dosing was indicated with empirically selected 2 antibiotics (one-dimension tailor-made therapy [1dTMT]).

Results:

Of 51 candidates with multiple eradication failures, 37 patients underwent the genotype test and AST, and 24 succeeded to obtain sufficient information to select 2 susceptible antibiotics. Of them, 22 patients accepted to receive 14-day 2dTMT. Of the residual patients, 12 accepted to receive 14-day 1dTMT. The mean eradication rate of 2dTMT was 86.4% (95% confidence interval [CI] 65.1%-98.8%) in intention-to-treat and 90.5% (95% CI 69.6%-98.8%) in per-protocol analyses, whereas that of 1dTMT was 75.0% (95% CI 42.8%-94.5%) in intention-to-treat and 90.0% (95% CI 55.5%-99.7%) in per-protocol analyses.

Conclusion:

Without vonoprazan, 14-day 2dTMT could be one of the salvage therapies for patients with multiple eradication failures. In cases of insufficient information with the AST, 14-day 1dTMT could be an alternative therapy. Clinical Trials Registry number, UMIN000022154 (https//www.umin.ac.jp/icdr/index.html).
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Gastro Hep Adv Año: 2022 Tipo del documento: Article País de afiliación: Japón

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Gastro Hep Adv Año: 2022 Tipo del documento: Article País de afiliación: Japón